Ontario Teachers Pension Plan Board Has $1.12 Million Position in Pfizer Inc. (NYSE:PFE)

Ontario Teachers Pension Plan Board lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 62.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,685 shares of the biopharmaceutical company's stock after selling 63,563 shares during the period. Ontario Teachers Pension Plan Board's holdings in Pfizer were worth $1,120,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its stake in Pfizer by 16.1% in the 3rd quarter. First Horizon Advisors Inc. now owns 691,228 shares of the biopharmaceutical company's stock valued at $20,004,000 after buying an additional 95,749 shares during the last quarter. Advisors Asset Management Inc. increased its position in Pfizer by 4.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 689,185 shares of the biopharmaceutical company's stock worth $19,945,000 after buying an additional 28,704 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Pfizer by 67.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock valued at $428,000 after acquiring an additional 5,959 shares during the period. Segall Bryant & Hamill LLC acquired a new stake in shares of Pfizer in the third quarter worth $2,123,000. Finally, Prospera Private Wealth LLC increased its position in Pfizer by 13.9% during the third quarter. Prospera Private Wealth LLC now owns 28,101 shares of the biopharmaceutical company's stock worth $813,000 after acquiring an additional 3,425 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Daiwa America raised Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and lifted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $32.92.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Trading Down 0.1 %

Shares of PFE stock traded down $0.02 during trading hours on Thursday, reaching $24.92. The company had a trading volume of 8,627,101 shares, compared to its average volume of 38,313,168. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a 50 day moving average of $28.36 and a 200 day moving average of $28.61. The firm has a market cap of $141.22 billion, a price-to-earnings ratio of 33.65, a P/E/G ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.17) EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.74%. The ex-dividend date is Friday, November 8th. Pfizer's payout ratio is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.